We admitted a 52-year-old woman to hospital for evaluation of a four-year history of progressive cognitive impairment, irritable affect, gait impairment and incontinence. Thirty years earlier, she had undergone surgery and whole-brain radiotherapy (50 Gy in 25 fractions) for a right frontal oligoden-droglioma. Her neurologic examination showed paratonia, primitive reflexes, hyperreflexia and difficulty initiating gait, despite preserved leg strength. Cognitive testing demonstrated impaired memory, naming and comprehension, as well as severe executive dysfunction as illustrated by impaired clock drawing1 (Figure 1). Magnetic resonance imaging of the brain showed postoperative changes and marked, abnormal, T2 signal hyperintensity involving white matter of frontal and parietal lobes bilaterally (Appendix 1, available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.101879/-/DC1).
Based on the clinical and radiologic findings, we diagnosed delayed radiation-induced leukoencephalopathy. This disease may occur months to several years following therapeutic cranial irradiation, and incidence estimates vary widely from 2% to 50%.2,3 Symptoms include progressive mental slowing and cognitive decline leading to frontal–subcortical dementia. It may be accompanied by gait difficulties and urinary incontinence. Magnetic resonance imaging will initially show progressive subcortical atrophy, followed by periventricular white matter changes and finally confluent white matter abnormalities, as in our patient. The degree of abnormality on imaging correlates with cognitive deficits.3
The risk of radiation-induced leukoencephalopathy appears to be related to the total dose of radiation (> 45–50 Gy), the concomitant use of chemotherapy, age at the time of radiotherapy and coexisting white matter disease such as multiple sclerosis or leukoaraiosis.2 Treatment is supportive, because no specific therapies are known to reverse the usually progressive course of this illness.
Acknowledgements
Alexandre Henri-Bhargava has been funded in part by a fellowship from Eli Lilly Canada. Morris Freedman is supported in part by the Saul A. Silverman Family Foundation as part of the Canada International Scientific Exchange Program.
Footnotes
-
Competing interests: None declared by Alexandre Henri-Bhargava. Morris Freedman is listed on a provisional patent related to diagnosis of Alzheimer disease versus frontotemporal dementia. He has received royalties for a book on clock drawing for cognitive assessment.1
-
This article has been peer reviewed.